Wire · operational-macro
Pearl Diagnostics Announces Publication of Clinical Studies Supporting FDA Clearance of ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 October 2026 · Fusion42 review
Pearl Diagnostics published clinical studies supporting FDA 510(k) clearance of the MycoMEIA Aspergillus Assay, a urine-based non-invasive test aiding diagnosis of invasive aspergillosis with 92% sensitivity. The assay offers a reliable alternative to invasive diagnostic methods and will be presented at IDWeek 2026.
This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 7 Oct 2026 and 8 Oct 2026.
◆ ◆ The Wire takeaway
Your Medtech venture just gained a new competitor with FDA clearance for non-invasive fungal infection testing via urine, shifting clinical demand away from invasive procedures. Now is the time to assess your diagnostic development plans against simpler, rapid urine-based assays.
◆ Coverage
3 sources · first reported 7 Oct 2026 · latest 8 Oct 2026
◆ Related on Wire
◆ Topics